CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 117 enrolled
Drug / intervention
Losartan +1 moredrug
Likely dose
Losartan 25 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04311177
NCT04311177Phase 2Completed
CompareCT.gov

Randomized Controlled Trial of Losartan for Patients With COVID-19 Not Requiring Hospitalization

University of Minnesota·interventional·Posted Mar 17, 2020·Updated May 4, 2022

In Brief

A Phase 2 clinical trial evaluating Losartan and Placebo for Corona Virus Infection and 2 related conditions. Completed, enrolled 117 participants across 4 sites.

Detailed Summary

This is a multi-center, double-blinded study of COVID-19 infected patients randomized 1:1 to daily losartan or placebo for 10 days or treatment failure (hospital admission).

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCorona Virus Infection, Acute Respiratory Distress Syndrome, SARS-CoV Infection
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
202120222023202420252026
First PostedMar 17, 2020
Enrollment StartApr 9, 2020
Primary CompletionFeb 1, 2021
TodayJul 2, 2026
Enrollment to primary: 10 monthsPosted 6.3 years ago

Interventions

Losartandrug

Losartan; 25 mg daily; oral administration

Placeboother

Placebo (microcrystalline methylcellulose, gelatin capsule); oral administration